Cover Image
市場調查報告書

T細胞白血病:開發中產品分析

T-Cell Leukemia - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 229778
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
T細胞白血病:開發中產品分析 T-Cell Leukemia - Pipeline Review, H2 2015
出版日期: 2015年09月16日 內容資訊: 英文 91 Pages
簡介

T細胞癌是知名的T細胞白血病,其特徵為難以抑制的白血球成長,而造成正常細胞欠缺。為此而影響免疫細胞,造成身體非常容易受感染。T細胞白血病的容易致病危險因子有暴露於放射線及化學藥品中。主要的症狀常以反復性感染、疼痛、出血,及疲勞等形式呈現,但可藉由化療,或幹細胞移植及藥物治療來控制症狀。

本報告提供T細胞白血病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關等資訊,以及最新的新聞和發表。

簡介

  • 調查範圍

T細胞白血病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

T細胞白血病:企業開發中的治療藥

T細胞白血病:大學/機關研究中的治療藥

T細胞白血病:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

T細胞白血病:企業開發中的產品

T細胞白血病:大學/機關研究中的產品

T細胞白血病的治療藥的開發企業

  • Applied Immune Technologies Ltd
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chipscreen Biosciences Ltd
  • iDD biotech SAS
  • Kyowa Hakko Kirin
  • MediGene AG
  • Sanofi
  • Stemline Therapeutics, Inc.
  • Theravectys SA

T細胞白血病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AGS-67E
  • alemtuzumab
  • 阻礙HLA-A2的抗體
  • BMS-906024
  • CD38為目標的細胞治療
  • CS-055
  • IDD-003
  • INA-01
  • L-1AD3
  • lenalidomide
  • MMIG-202
  • mogamulizumab
  • 單株抗體
  • 糖蛋白質為目標的腫瘤溶解性病毒
  • SL-101
  • THV-02

T細胞白血病:最近的開發平台趨勢

T細胞白血病:暫停中的計劃

T細胞白血病:開發中止的產品

T細胞白血病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7107IDB

Summary

Global Markets Direct's, 'T-Cell Leukemia - Pipeline Review, H2 2015', provides an overview of the T-Cell Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding T-Cell Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • T-Cell Leukemia Overview
  • Therapeutics Development
    • Pipeline Products for T-Cell Leukemia - Overview
    • Pipeline Products for T-Cell Leukemia - Comparative Analysis
  • T-Cell Leukemia - Therapeutics under Development by Companies
  • T-Cell Leukemia - Therapeutics under Investigation by Universities/Institutes
  • T-Cell Leukemia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • T-Cell Leukemia - Products under Development by Companies
  • T-Cell Leukemia - Products under Investigation by Universities/Institutes
  • T-Cell Leukemia - Companies Involved in Therapeutics Development
    • Applied Immune Technologies Ltd
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Chipscreen Biosciences Ltd
    • iDD biotech SAS
    • Kyowa Hakko Kirin Co., Ltd.
    • MediGene AG
    • Sanofi
    • Stemline Therapeutics, Inc.
    • Theravectys SA
  • T-Cell Leukemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGS-67E - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alemtuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-906024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target CD38 for cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CS-055 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDD-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INA-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • L-1AD3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MMIG-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mogamulizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • THV-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • T-Cell Leukemia - Recent Pipeline Updates
  • T-Cell Leukemia - Dormant Projects
  • T-Cell Leukemia - Discontinued Products
  • T-Cell Leukemia - Product Development Milestones
    • Featured News & Press Releases
      • Mar 23, 2015: THERAVECTYS Granted Authorization by the French National Agency for Medicines to Produce Lentiviral Vectors for Clinical Use and CAR-T Cell Therapies under GMP Standards
      • Feb 04, 2015: THERAVECTYS Obtains Orphan Drug Designation from the European Medicines Agency for Its Lentiviral Vector-Based Therapeutic Vaccine against Adult T-Cell Leukemia and Lymphoma
      • Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab
      • Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
      • Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe
      • Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
      • May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan
      • Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity
      • Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for T-Cell Leukemia, H2 2015
  • Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • T-Cell Leukemia - Pipeline by Applied Immune Technologies Ltd, H2 2015
  • T-Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2015
  • T-Cell Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • T-Cell Leukemia - Pipeline by Celgene Corporation, H2 2015
  • T-Cell Leukemia - Pipeline by Chipscreen Biosciences Ltd, H2 2015
  • T-Cell Leukemia - Pipeline by iDD biotech SAS, H2 2015
  • T-Cell Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
  • T-Cell Leukemia - Pipeline by MediGene AG, H2 2015
  • T-Cell Leukemia - Pipeline by Sanofi, H2 2015
  • T-Cell Leukemia - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • T-Cell Leukemia - Pipeline by Theravectys SA, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • T-Cell Leukemia Therapeutics - Recent Pipeline Updates, H2 2015
  • T-Cell Leukemia - Dormant Projects, H2 2015
  • T-Cell Leukemia - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for T-Cell Leukemia, H2 2015
  • Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top